Form 4: Klotho Neurosciences Director Acquires 20,000 Stock Options

Klotho Neurosciences Director Riad El-Dada acquired 20,000 non-qualified stock options at an exercise price of $0.41, bringing his total beneficial ownership to 60,000 options.

Summary

• Riad Hussein El-Dada, a Director of Klotho Neurosciences, Inc. (KLTO), acquired 20,000 non-qualified stock options on December 10, 2025.
• The options have an exercise price of $0.41 per share.
• Following this transaction, El-Dada beneficially owns a total of 60,000 derivative securities (options).
• The acquired options are fully vested and can be exercised at any time.
• The expiration date for these options is January 16, 2035.

Sentiment

Score: 7

Explanation: The acquisition of additional stock options by a director generally indicates confidence in the company's future performance, which is a positive signal for investors.

Positives

• A director increasing their beneficial ownership through option grants can signal confidence in the company's future prospects.
• The options are fully vested and immediately exercisable, providing flexibility to the director.

Future Outlook

N/A

Industry Context

N/A

Related Party Transactions

• The acquisition of 20,000 non-qualified stock options by Director Riad Hussein El-Dada from Klotho Neurosciences, Inc. at an exercise price of $0.41 per share.

Stakeholder Impact

• Shareholders: May view the director's increased ownership as a positive signal of confidence in the company's future.
• Employees/Management: Reinforces alignment of interests between leadership and company performance.

Key Dates

Recommendation

The acquisition of 20,000 stock options by a director is a positive indicator of insider confidence in Klotho Neurosciences' future. However, this single transaction, without additional financial or operational context, is typically insufficient to change a broader investment thesis. It reinforces a 'hold' position for existing investors, suggesting continued monitoring of the company's performance.

Keywords

Klotho Neurosciences, KLTO, Form 4, Insider Trading, Stock Options, Director, Beneficial Ownership, Riad El-Dada, Neurosciences